Literature DB >> 28719177

Classics in Neuroimaging: Imaging the Dopaminergic Pathway with PET.

Meghna Kanthan1, Paul Cumming2,3, Jacob M Hooker4,5, Neil Vasdev1,5.   

Abstract

The success of positron emission tomography (PET) for observing molecular processes underlying brain function and disease is underpinned by radiotracer chemistry. From the earliest applications of PET to measure dopamine synthesis capacity and the abundance of neuroreceptors and transporters, to the more recent topic of dynamic neurochemical imaging, interrogation of brain dopamine in conditions such as neurodegenerative diseases, schizophrenia, mood disorders, and addictions has been a driving force that challenges the ingenuity of radiopharmaceutical scientists. In fact, the pursuit of new ligands and reaction methods to address longstanding challenges has often been pioneered in the context of dopamine imaging. From this viewpoint, we highlight the unique history of imaging the dopaminergic pathway with PET, and present our interpretation of how this worldwide effort shaped and continues to drive the field of molecular imaging.

Entities:  

Keywords:  PET; dopaminergic pathway; molecular imaging

Mesh:

Substances:

Year:  2017        PMID: 28719177     DOI: 10.1021/acschemneuro.7b00252

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  3 in total

1.  Fluorine-18: an untapped resource in inorganic chemistry.

Authors:  Cassis Varlow; Daniel Szames; Kenneth Dahl; Vadim Bernard-Gauthier; Neil Vasdev
Journal:  Chem Commun (Camb)       Date:  2018-10-18       Impact factor: 6.222

Review 2.  The chemical tools for imaging dopamine release.

Authors:  Michael R Post; David Sulzer
Journal:  Cell Chem Biol       Date:  2021-04-23       Impact factor: 9.039

3.  Development of a Dual Fluorescent and Magnetic Resonance False Neurotransmitter That Reports Accumulation and Release from Dopaminergic Synaptic Vesicles.

Authors:  Michael R Post; Wei-Li Lee; Jia Guo; Dalibor Sames; David Sulzer
Journal:  ACS Chem Neurosci       Date:  2021-11-24       Impact factor: 4.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.